Evidence map›Paper›PMID 39785683›Full record

ArticleCancer research communications2025

Targeting Pancreatic Cancer Cell Stemness by Blocking Fibronectin-Binding Integrins on Cancer-Associated Fibroblasts.

Chengsheng Wu, Tami Von Schalscha, Diva Sansanwal, Chen Qian, Qinlin Jiang, Ryan M Shepard, Hiromi I Wettersten, Stephen J McCormack, Sara M Weis, David A Cheresh

Abstract read
In one paragraph

Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chengsheng Wu *Department of Pathology, Moores Cancer Center, Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0009-0003-3091-1606
Tami Von Schalscha *Department of Pathology, Moores Cancer Center, Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0009-0007-8348-6200
Diva SansanwalDepartment of Pathology, Moores Cancer Center, Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0009-0003-4405-6962
Chen QianDepartment of Pathology, Moores Cancer Center, Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0009-0005-0016-8043
Qinlin JiangDepartment of Pathology, Moores Cancer Center, Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0009-0001-8724-6171
Ryan M ShepardDepartment of Pathology, Moores Cancer Center, Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0000-0002-7488-369X
Hiromi I WetterstenDepartment of Pathology, Moores Cancer Center, Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0000-0001-7144-3122
Stephen J McCormackAlpha Beta Therapeutics, Inc., Claremont, California.ORCID 0009-0005-6344-9651
Sara M WeisDepartment of Pathology, Moores Cancer Center, Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0009-0008-3137-4239
David A ChereshDepartment of Pathology, Moores Cancer Center, Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California.ORCID 0000-0002-7193-8595

Funding

Attacking stress tolerance in cancerR35CA220512 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHERESH, DAVID A · 2018 to 2024
$6.5M
αvβ3-induced epithelial cancer progression via macrophage recruitmentK01OD030513 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WETTERSTEN, HIROMI INOUE · 2021 to 2025
$647k
National Institutes of Health (NIH) CA220512NCI NIH HHS R35 CA220512NIH HHS K01 OD030513University of California Tobacco-Related Disease Research Program (TRDRP) T29FT0343
6 · The paper itself

Abstract

abstractCancer-associated fibroblasts (CAF) generate an extracellular matrix (ECM) which provides a repository for factors that promote pancreatic cancer progression. In this study, we establish that CAF contribution to pancreatic tumor initiation, i.e., stemness, depends on fibronectin (FN) as a scaffold required for assembly of a collagen-containing fibrotic ECM with a critical dependence on the FN-binding integrins, α5β1 and αvβ3. CAF matrix assembly can be prevented by knockdown of FN, integrin α5, or integrin β3 or by a bispecific antibody with dual recognition of α5β1 and αvβ3 that can also destabilize a preexisting matrix. In mice, the ability of CAFs to produce a stiff collagenous matrix and accelerate tumor initiation can be blocked by knockdown of FN or FN-binding integrins or systemic treatment with the α5β1/αvβ3 bispecific antibody. Together, these results reveal that dual targeting of the FN-binding integrins, α5β1 and αvβ3, can block the ability of CAFs and their matrix to enhance pancreatic cancer stemness and progression. SIGNIFICANCE: Simultaneous targeting of two integrins that function as receptors for FN, a protumor ECM protein, can prevent fibroblasts from supporting the malignant behavior of pancreatic cancer cells.

Indexed as

FibronectinsIntegrinsNeoplastic Stem CellsPancreatic NeoplasmsAnimalsCell Line, TumorCell Transformation, NeoplasticCollagenFemaleFibroblastsHumansMiceMice, NudeProtein BindingStress, PsychologicalCollagenFibronectinsIntegrins

Identifiers

PMID39785683
PMCPMC11783622

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.